EVMN
Evommune, Inc.
NYSE · Healthcare · Biotechnology · US
$9.65
+2.99%Next report
Analyst consensus
- Next report date
- Oct 16, 2026
- EPS estimate
- -$0.82
- Revenue estimate
- $333.3K
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- -$0.89
- EPS estimate
- -$0.66
- Revenue actual
- —
- Revenue estimate
- $1.3M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 1
- EPS misses (12Q)
- 3
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -236.1%
- Revenue beats (12Q)
- 1
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $24
- PT range
- $21 – $28
- Analysts
- 6
4 Buy2 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 6, 2026 | -$0.66 | -$0.89 | Miss -33.94% | — |
| May 7, 2026 | -$0.83 | -$0.64 | Beat 22.89% | — |
| Mar 5, 2026 | -$0.82 | -$1.43 | Miss -75.00% | — |
| Dec 11, 2025 | -$0.84 | -$8.07 | Miss -858.43% | $10.0M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Oct 16, 2026